A Single Institution Experience with Weekly Intramuscular Methotrexate for Nonmetastatic Gestational Trophoblastic Disease

The purpose of this study is to report our experience with weekly intramuscular methotrexate for nonmetastatic gestational trophoblastic disease. Treatment was begun at a dose of 40 mg/m2and escalated weekly by 5–10 mg/m2, depending upon response and tolerance, to a maximum dose of 60 mg/m2. Remissi...

Full description

Saved in:
Bibliographic Details
Published in:Gynecologic oncology 1996-02, Vol.60 (2), p.292-294
Main Authors: Hoffman, Mitchel S., Fiorica, James V., Gleeson, Noreen C., Roberts, William S., Cavanagh, Denis
Format: Article
Language:English
Subjects:
Adolescent
Adult
Antineoplastic agents
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Biological and medical sciences
Chemotherapy
Chorionic Gonadotropin, beta Subunit, Human - administration & dosage
Cyclophosphamide - administration & dosage
Dactinomycin - administration & dosage
Drug Administration Schedule
Etoposide - administration & dosage
Female
Humans
Hydatidiform Mole - drug therapy
Injections, Intramuscular
Medical sciences
Methotrexate - administration & dosage
Pharmacology. Drug treatments
Pregnancy
Remission Induction
Uterine Neoplasms - drug therapy
Vincristine - administration & dosage
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The purpose of this study is to report our experience with weekly intramuscular methotrexate for nonmetastatic gestational trophoblastic disease. Treatment was begun at a dose of 40 mg/m2and escalated weekly by 5–10 mg/m2, depending upon response and tolerance, to a maximum dose of 60 mg/m2. Remission was induced with weekly intramuscular methotrexate alone in 12 (60%) of 20 patients in 2–12 (median 8) weeks. The remaining 7 patients had a complete response to alternate chemotherapy. There were no major toxicities. Although the results of the present study are less favorable in terms of response, the overall published results using weekly intramuscular methotrexate for nonmetastatic gestational trophoblastic disease indicate that it is comparable in efficacy to other first-line treatments while having the advantages of convenience, low cost, and low toxicity.
ISSN:0090-8258
1095-6859
DOI:10.1006/gyno.1996.0041